Judging from the risk ability of the fund
The main issuer of Shenwan Lingxin Zhongzheng Shenwan medical biological products is Shenwan Lingxin Fund, which was established on June 5438+ 10, 2004. Shen Yin Wanguo Securities Co., Ltd. and Mitsubishi UFJ Trust Bank Co., Ltd. jointly initiated the establishment of a Sino-foreign joint venture fund management company, with strong anti-risk ability and professional ability, and a deep qualification page for fund managers.
Shenwan Lingxin Zhongzheng Shenwan Pharmaceutical Bio was founded in June 2065438+2005, less than 5 years ago. It is a relatively strong fund product and belongs to a low-risk fixed expected income fund. Compared with other similar funds, the expected income level is the same. Strive for long-term stable appreciation of fund assets.
From the perspective of capital operation ability
1, growth situation
Shenwan Lingxin Zhongzheng Shenwan Pharmaceutical Biology was initiated and established by Shenwan Lingxin Fund. The company's operating ability is good, and the fund's profitability has great development prospects. The current situation of the fund ranks in a quarter, and it has performed well since its establishment. The expected income level in the past year is average, and the long-term profitability has steadily improved.
2. Expected income
By the end of 2019-1-15, the net value of Shenwan Pharmaceutical Bio-unit in Shenwan Lingxin was 1.0 180, which increased by1in the ranking of similar funds in recent three years. The fund strives for long-term steady appreciation, with an increase of 22.23% since its establishment.
All the above opinions about Shen Wanling's medical biology are for reference only, and I hope they will help you. Warm reminder, financial management is risky and investment needs to be cautious.